We report, to the best of our knowledge, the first case of Bowen disease treated with tirbanibulin. In addition to the successful treatment of the malignant lesions, the improvement in skin texture and photodamage is remarkable. With a good safety profile, tolerability and the dosing convenience of this new drug, we believe that its use in pathologies beyond Olsen grade 1 actinic keratoses is promising, but further studies are required.
4 January 2023 in Australasian Journal of Dermatology